Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 14-23

  Zhang, B ^a   Dong, L W ^a   Tan, Y X ^a   Zhang, J ^a   Pan, Y F ^a   Yang, C ^a   Li, M H ^a   Ding, Z W ^a   Liu, L J ^a   Jiang, T Y ^a   Yang, J H ^a   Wang, H Y ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ASPARAGINASE; ASPARTATE AMMONIA LIGASE; PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; DRUG TARGETING; ENCAPSULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION;

ADULT; ALPHA-FETOPROTEINS; ANIMALS; ASPARAGINASE; ASPARTATE-AMMONIA LIGASE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SURVIVAL; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880273922     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.293     Document Type: Article

References (34)

1. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13(3): 335-342.
2. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K (2005) Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130(6): 860-868.
3. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R (2006) Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 107(11): 4244-4249.
4. Aslanian AM, Fletcher BS, Kilberg MS (2001) Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT- 4 human leukaemia cells. Biochem J 357(Pt 1): 321-328.
5. Chen H, Pan YX, Dudenhausen EE, Kilberg MS (2004) Amino acid deprivation induces the transcription rate of the human asparagine synthetase gene through a timed program of expression and promoter binding of nutrient-responsive basic region/leucine zipper transcription factors as well as localized histone acetylation. J Biol Chem 279(49): 50829-50839.
6. Cui H, Darmanin S, NatsuisakaM, Kondo T, AsakaM, Shindoh M, Higashino F, Hamuro J, Okada F, Kobayashi M, Nakagawa K, Koide H (2007) Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res 67(7): 3345-3355.
7. den Boer ML, Evans WE, Pieters R (2005) TELAML1-positive ALL: a discordant genotype. Cell Cycle 4(8): 997-998.
8. Dong LW, Hou YJ, Tan YX, Tang L, Pan YF, Wang M, Wang HY (2011) Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy 7(10): 1222-1229.
9. Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL, Godfrin Y (2012) Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas 41(6): 940-948.
10. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12): 1118-1127.
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
12. Gong SS, Basilico C (1990) A mammalian temperature-sensitive mutation affecting G1 progression results from a single amino acid substitution in asparagine synthetase. Nucleic Acids Res 18(12): 3509-3513.
13. Greco A, Ittmann M, Basilico C (1987) Molecular cloning of a gene that is necessary for G1 progression in mammalian cells. Proc Natl Acad Sci USA 84(6): 1565-1569.
14. Haskell CM (1981) L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms. Cancer Treat Rep 65(Suppl 4): 57-59.
15. Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg MS (1997) Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol 272(5 Pt 1): C1691-C1699.
16. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D (2007) Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117(4): 1049-1057.
17. Kilberg MS, Barbosa-Tessmann IP (2002) Genomic sequences necessary for transcriptional activation by amino acid deprivation of mammalian cells. J Nutr 132(7): 1801-1804.
18. Lorenzi PL, Llamas J, GunsiorM, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC, Goldsmith PK, Birrer MJ, Weinstein JN (2008) Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 7(10): 3123-3128.
19. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5(11): 2613-2623.
20. Okada S, Hongo T, Yamada S, Watanabe C, Fujii Y, Ohzeki T, Horikoshi Y, Ito T, Yazaki M, Komada Y, Tawa A (2003) In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia. Br J Haematol 123(5): 802-809.
21. Prager MD, Bachynsky N (1968) Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. Biochem Biophys Res Commun 31(1): 43-47.
22. Pui CH, Relling MV, Campana D, Evans WE (2002) Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 6(2): 161-180, discussion 200-2.
23. Richards NG, Kilberg MS (2006) Asparagine synthetase chemotherapy. Annu Rev Biochem 75: 629-654.
24. Richards NG, Schuster SM (1998) Mechanistic issues in asparagine synthetase catalysis. Adv Enzymol Relat Areas Mol Biol 72: 145-198.
25. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD (2009) Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 3(4): 353-367.
26. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W (2012) Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3): 895-903.
27. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, Stigter RL, van Wering ER, Janka-Schaub GE, Slater R, Pieters R (2003) Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)pediatric ALL. Blood 101(7): 2743-2747.
28. StamsWA, den BoerML, Holleman A, Appel IM, Beverloo HB, vanWering ER, Janka-Schaub GE, Evans WE, Pieters R (2005) Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 105(11): 4223-4225.
29. Tardito S, Chiu M, Uggeri J, Zerbini A, Da Ros F, Dall'Asta V, Missale G, Bussolati O (2011) L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets 11(8): 929-943.
30. Tezuka K, Nakayama H, Honda K, Suzumiya J, Oshima K, Kitoh T, Ishii E (2002) Treatment of a child with myeloid/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation. Int J Hematol 75(2): 201-206.
31. Verma N, Kumar K, Kaur G, Anand S (2007) L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol 27(1): 45-62.
32. Wang Q, Tan YX, Ren YB, Dong LW, Xie ZF, Tang L, Cao D, Zhang WP, Hu HP, Wang HY (2011) Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis. BMC Cancer 11: 271.
33. Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, Okitsu Y, Fukuhara N, Ohba-Ohtsuka R, Kohata K, Ishizawa K, Kameoka J, Harigae H (2010) Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type. Leuk Lymphoma 51(8): 1509-1512.
34. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJ (2002) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99(1): 245-251.